Pharmagreen Biotech Inc.
PHBIdata completeness 63%5 fiscal years on fileData notes: no data for concept 'revenue'
i. The business — what you’d actually own
| Figure | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net income | −$1.07M1 | −$767,5372 | −$2.48M3 | −$4.53M4 | −$875,5054 |
| Operating cash flow | −$785,5345 | −$317,8326 | −$607,6347 | −$206,0818 | −$426,5688 |
| Capital expenditure | $251,3109 | $196,12710 | — | — | — |
| Free cash flow (derived) | −$1.04M5 | −$513,9596 | — | — | — |
| Total debt | — | — | $30,02811 | — | — |
| Cash & equivalents | — | $62,68212 | $12,19612 | $25,30012 | $8,01613 |
| Diluted shares | 293.1M | 364.9M | 388.4M | 326.0M | 218.7M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.08
your share of equity
Profit it earned you last year
−$0.04
Free cash flow it threw off
—
Debt you’d be carrying
—
10 shares is a claim on −$0.08 of net worth that earned you −$0.04 last year.
iii. Is this a good business?
Moat signal · return on equity
— avg · 5y
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Management signal · capital allocation
−25% shares · 5y
Share count is down 25% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 2 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined
Different models answer different questions — which to trust when →
Sources — the receipts
- 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (NetIncomeLoss)
- 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (NetIncomeLoss)
- 10-K · period ending 2020-09-30 · accession 0001477932-21-009538 (NetIncomeLoss)
- 10-K · period ending 2021-09-30 · accession 0001477932-23-000296 (NetIncomeLoss)
- 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2020-09-30 · accession 0001477932-21-009538 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-09-30 · accession 0001477932-23-000296 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2018-09-30 · accession 0001273511-19-000126 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2019-09-30 · accession 0001273511-21-000011 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2020-09-30 · accession 0001273511-21-000011 (LongTermDebtNoncurrent)
- 10-K · period ending 2019-09-30 · accession 0001477932-21-009538 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-09-30 · accession 0001477932-23-000296 (CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents)